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Background: Bell’s palsy or acute idiopathic lower motor neurone facial paralysis is characterized by sudden onset
paralysis or weakness of the muscles to one side of the face controlled by the facial nerve. While there is high level
evidence in adults demonstrating an improvement in the rate of complete recovery of facial nerve function when
treated with steroids compared with placebo, similar high level studies on the use of steroids in Bell’s palsy
in children are not available. The aim of this study is to assess the utility of steroids in Bell’s palsy in children
in a randomised placebo-controlled trial.
Methods/Design: We are conducting a randomised, triple-blinded, placebo controlled trial of the use of prednisolone
to improve recovery from Bell’s palsy at 1 month. Study sites are 10 hospitals within the Australian and New Zealand
PREDICT (Paediatric Research in Emergency Departments International Collaborative) research network. 540 participants
will be enrolled. To be eligible patients need to be aged 6 months to < 18 years and present within 72 hours of onset
of clinician diagnosed Bell’s palsy to one of the participating hospital emergency departments. Patients will
be excluded in case of current use of or contraindications to steroids or if there is an alternative diagnosis.
Participants will receive either prednisolone 1 mg/kg/day to a maximum of 50 mg/day or taste matched
placebo for 10 days. The primary outcome is complete recovery by House-Brackmann scale at 1 month. Secondary
outcomes include assessment of recovery using the Sunnybrook scale, the emotional and functional wellbeing of the
participants using the Pediatric Quality of Life Inventory and Child Health Utility 9D Scale, pain using Faces Pain Scale
Revised or visual analogue scales, synkinesis using a synkinesis assessment questionnaire and health utilisation costs at
1, 3 and 6 months. Participants will be tracked to 12 months if not recovered earlier. Data analysis will be by intention
to treat with primary outcome presented as differences in proportions and an odds ratio adjusted for site and age.
Discussion: This large multicenter randomised trial will allow the definitive assessment of the efficacy of prednisolone
compared with placebo in the treatment of Bell’s palsy in children.
Trial registration: The study is registered with the Australian New Zealand Clinical Trials Registry
ACTRN12615000563561 (1 June 2015).
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Bell’s palsy, also known as acute idiopathic lower motor
neurone facial paralysis, is characterized by sudden onset
paralysis or weakness of the muscles to one side of the
face controlled by the facial nerve. Bell’s palsy is an idio-
pathic, presumed immune mediated phenomenon, pos-
sibly with an infection as the inciting event [1–3]. In
addition to the muscles of facial expression, the affected
seventh cranial nerve in Bell’s palsy also supplies the
taste buds to the anterior two thirds of the tongue, mus-
cles associated with hearing, and the salivary and lacri-
mal glands. The early effect of Bell’s palsy is an inability
to fully close the mouth and eye on the affected side of
the face, causing difficulties in eating and speaking, cor-
neal drying and erosion. Later symptoms can include
pain around the ear sometimes extending to the back of
head/neck, altered taste, synkinesis (involuntary facial
movements), facial spasm, facial contracture, dysfunc-
tional lacrimation (corneal drying and/or crocodile tears)
and noise intolerance [2]. The resulting impairment of
oral competence, verbal communication and social inter-
action, can contribute to significant emotional distress
during Bell’s palsy [4–7].
Data from the United Kingdom reported an incidence
of Bell’s palsy of more than 6 per 100,000 person-years
in children under 14 years and more than 20 per
100,000 person-years in people aged 15–29 years [8],
although the true incidence may be higher [9]. In an
emergency department based study of stroke mimics in
children [10] Bell’s palsy was the third most frequent
diagnosis in children with sudden onset neurological
dysfunction. In adults, up to 30 % of untreated patients
fail to make a complete recovery [11]. While in children
up to 100 % recover from Bell’s palsy within 12 months,
it often leaves them with a prolonged period of func-
tional impairment, disfigurement and emotional dis-
tress [4, 12–16].
The main agents used for the treatment of Bell’s palsy
are steroids. The anti-inflammatory effect of steroids
(such as prednisolone) is assumed to minimize facial
nerve swelling, compression and damage, therefore re-
ducing the length of time to and increasing the likeli-
hood of recovery [2, 17]. Two recent, large, blinded
randomised controlled trial (RCTs) of steroids in adults
[18, 19] (combined n = 1309) reported statistically and
clinically significant improvements in the proportion
who reached complete recovery when Bell’s palsy was
treated with steroids compared with placebo. The partic-
ipants in both studies were randomised to receive pred-
nisolone and acyclovir, prednisolone and placebo,
acyclovir and placebo or placebo and placebo. One of
the studies, by Engstrom et al. (839 patients), showed
shorter times to recovery for patients who received pred-
nisolone compared with those who did not (combiningthose who did and did not receive acyclovir, hazard ratio
1.4 95 % confidence interval [CI] 1.18 to 1.64; p < 0.0001)
[19]. The other study (Sullivan et al., 496 patients) found
that more patients had complete recovery by 3 months in
the group who received prednisolone (83 %) compared
with placebo (63 %) (again combining participants who
did and did not receive acyclovir, difference 19.4 %; 95 %
CI: 11.7 to 27.1 %); number needed to treat to achieve one
additional complete recovery was 6 (95 % CI: 4 to 9) [18].
A recent (2010) Cochrane review (8 trials, n = 1569) on
treatment for Bell’s palsy [17], including the two RCTs
above, found that corticosteroid treated patients had a
lower risk of incomplete recovery than placebo treated pa-
tients (relative risk [RR] 0.71; 95 % CI 0.61 to 0.83) and
that those treated with corticosteroids also had reduced
risk of synkinesis during follow up (RR 0.6; 95 % CI 0.44
to 0.81). Subsequently, in 2012 the American Academy
of Neurology released a guideline update on the use of
steroids and antivirals to treat Bell’s palsy [20]. It con-
cluded that steroids have proven efficacy in treating
Bell’s palsy in adults, and that no further research is re-
quired. Similarly, in 2013 the American Academy of
Otolaryngology-Head and Neck Surgery Foundation
published a clinical practice guideline recommending
the use of oral steroids within 72 hours in patients with
Bell’s palsy 16 years and older [21].
Despite the conclusive evidence of benefit from ste-
roids in adults with Bell’s palsy, two systematic review of
the use of steroids to treat Bell’s palsy in children found
no placebo controlled trials [13, 22]. There has only
been one small randomised trial of steroid use in chil-
dren with Bell’s palsy. Unüvar et al. [12] randomised 42
children (mean age 53 months) to receive 1 mg/kg/day
of methylprednisolone or no treatment (no placebo).
The study found that all children fully recovered within
12 months regardless of treatment. However, at 4 and
6 months after treatment, more children in the methyl-
prednisolone group had recovered compared with the
no treatment group (86 vs 72 % at 4 months and 100 vs
85 % at 6 months). These findings suggest that although
children eventually recover, steroids hasten the time to
recovery. The lack of a placebo arm, small patient num-
bers, and inclusion of only children with severe signs
and symptoms at presentation limit the generalisability
of these results. Two systematic reviews of the use of
steroids to treat Bell’s palsy in children found no placebo
controlled trials and either state that there was insuffi-
cient evidence to make a treatment recommendation
[13] or provide no positive evidence for the beneficial ef-
fects of corticosteroids and do not recommend the rou-
tine use of steroids in children [22]. The results from
adult studies of steroids to treat Bell’s palsy are difficult
to extrapolate to children as medical conditions often
manifest differently and have different responses to
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are documented differences from adults in the patho-
physiology [23] and natural history of other paediatric
demyelinating conditions: (i) acute disseminated en-
cephalomyelitis, which is typically monophasic, has
different presenting features and involves different
brain structures than similar diseases in adults (such
as multiple sclerosis) [24, 25]; (ii) acute myelitis can
have a good prognosis in children but usually has a
poor prognosis in adults [26]. Similarly, it is unclear
whether the pathophysiology in children is different
from adults.
Both systematic reviews of the use of steroids to treat
Bell’s palsy in children [13, 22] call for a definitive trial
to be conducted. The American Academy of Neurology
similarly called for RCTs to determine if Bell’s palsy in
children should be treated with steroids [20]. The
American Academy of Otolaryngology-Head and Neck
Surgery Foundation clinical practice guideline states that
corticosteroids may be considered in pediatric patients
with a large role for care giver involvement in the deci-
sion making process [21]. A consequence of the lack of
evidence and firm treatment recommendations is vari-
able use of steroid in children reported from a number
of centers [4, 13, 14, 16].
Based on the lack of placebo-controlled evidence for
or against steroid use in Bell’s palsy in children and the
resulting variability in care, and the high level evidence
of the efficacy of prednisolone in adults we designed a
study with the primary aim to determine, in children
aged between 6 months and less than 18 years present-
ing to the emergency department (ED) with symptoms
of Bell’s palsy (unilateral, peripheral facial nerve palsy),
whether treatment with oral prednisolone (at ~1 mg/kg
daily for 10 days) increases the proportion of children
who have complete recovery at 1 month (defined as
grade 1 on the House-Brackmann (HB) scale [18, 27])
compared with children receiving placebo. This study
will also provide a unique insight into Bell’s palsy re-
lated questions including the time to complete recov-
ery; the emotional and functional impact of Bell’s
palsy; the effect of initial severity and time to treat-
ment on subsequent recovery; and the nature of pain,
motor synkinesis and autonomic dysfunction in chil-
dren with Bell’s palsy.
Methods
Study design
This is a phase III, triple-blinded, randomised, placebo-
controlled superiority trial of prednisolone for treatment
of Bell’s palsy. Participants will be randomised in a 1:1
ratio to receive ~ 1 mg/kg/day of prednisolone, up to a
maximum of 50 mg, or matched placebo for 10 days. The
study will include a total of 540 children (approximately270 in each treatment group). This sample size allows for
10 % loss to follow-up at 1 month. The study will be con-
ducted at sites of the Paediatric Research in Emergency
Departments International Collaborative (PREDICT) re-
search network in Australia and New Zealand [28]. The
central study site is the Murdoch Childrens Research In-
stitute in Melbourne (MCRI), Australia and the central
study pharmacy is at the co-located Royal Children’s
Hospital (RCH), Melbourne, Australia.
Outcomes
Primary outcome
The primary outcome is complete recovery at 1 month
post randomisation, where recovery is defined as a
House Brackmann score of 1 [18, 27]. Recovery will be
assessed face-to-face by a site specialist clinician who
may be a pediatric neurologist, ear-nose-throat (ENT)
specialist, pediatrician or ED physician. Where the par-
ticipant is unable to attend the study site, it may be
completed via videoconference using an online tool.
There are several different tools used in studies to de-
scribe the degree of facial dysfunction of Bell’s palsy, in-
cluding the House Brackmann (HB) [12, 18, 19, 29–31],
Sunnybrook [19, 32], Facial Paralysis Recovery Index/
Profile [29, 33], and Yanagihara grading systems [34, 35].
The two largest adult RCTs used Sunnybrook scale and
HB scale, or the HB scale alone [18, 19], and the only
RCT of steroids for treating Bell’s palsy in children from
Unüvar et al. [12] used the HB scale to assess recovery.
In line with these studies, the primary tool to determine
outcome in this study is the HB scale as used slightly
modified by Sullivan et al. [36].
Using the HB scale, the two largest adult studies defined
recovery as reaching a HB grade of 1 (HB 1) [18, 19];
others, including Unüvar [12], used HB grade 1 or 2. Sulli-
van et al. [18] initially set ‘complete recovery’ at HB grade
1 or 2, however, very early in the study the investigators
found that participants only looked and felt fully recov-
ered once HB grade 1 was obtained and hence changed
their definition to HB grade 1. Our study accordingly de-
fines full recovery as having achieved HB grade 1.
There are currently limited data regarding how long it
takes children to recover from Bell’s palsy but existing
data suggest a more rapid recovery in children than in
adults [4, 12, 14, 37]. Unüvar’s study of 42 children [12]
found that 72 % of children had complete recovery at
four months, 85 % at six months, and 100 % recovery at
12 months without steroids. In two paediatric observa-
tional studies [4, 14], the mean time to recovery was five
weeks (range 1–21 weeks) and 59 % had recovered at
1 month without steroids. Therefore the primary out-
come in the current study was chosen as complete re-
covery at 1 month with recovery at 3 and 6 months as
secondary outcomes.
Table 1 Inclusion and Exclusion Criteria
Inclusion criteria
1. Be aged from 6 months to less than 18 years of age.
2. Weight ≥5 kg.
3. Be diagnosed with Bell’s palsy by their treating doctor.
4. Have acute onset of symptoms of Bell’s palsy for less than
72 hours prior to randomisation.
5. Have written informed consent provided by the parent(s) or legal
guardian. The participant, where he/she is deemed competent to
provide consent, may also provide written consent.
Exclusion criteria
1. Likely to be unable to complete the 1 month study assessment
of Bell’s palsy symptoms. Where the participant is unable to attend
the study site, the assessment can be completed via videoconferencing
using skype software or other online tools.
2. Previously randomised into the study.
3. Contraindication to prednisolone, including: active or latent
tuberculosis, systemic fungal infection, known hypersensitivity to
prednisolone or any of the excipients in the liquid, diminished
cardiac function, diabetes mellitus, peptic ulcer or chronic renal
failure, multiple sclerosis, recent active herpes zoster or chickenpox.
4. Use of any systemic or inhaled steroid within 2 weeks prior to the
onset of symptoms.
5. Current or past oncological diagnosis.
6. Pregnancy.
7. Breast feeding.
8. Currently receiving concomitant medications in which prednisolone
is contraindicated.
9. Immunisation with a live vaccine within the previous 1 month.
10. Requirement for a live vaccine within 6 weeks of the first dose of
study drug.
11. Signs of upper motor neurone VII nerve palsy (weakness of the
lower half of the face only).
12. Diagnosis by a medical doctor of acute otitis media concurrently
or within 1 week prior to the onset of Bell’s palsy symptoms.
13. Evidence of vesicles on the ear drum suggestive of herpes zoster
related Ramsay Hunt syndrome.
14. Known facial trauma within 1 week prior to the onset of
symptoms that in the view of the clinician may have caused or
contributed to facial palsy.
15. Any other condition at risk of being influenced by the study
treatment or that might affect completion of the study.
16. Any concern regarding parent/guardian/participant ability to
comply with the study protocol.
17. Prior episode of Bell’s palsy.
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The secondary outcomes are:
1. Complete recovery at 1 month using the
Sunnybrook scale [32, 38]
2. Complete recovery at 3 months using the
Sunnybrook scale
3. Complete recovery at 3 months using the HB scale
4. Complete recovery at 6 months using the
Sunnybrook scale
5. Complete recovery at 6 months using the HB scale
6. Complete recovery at 1, 3 and 6 months using the
HB scale according to age, time to treatment and
initial severity
7. Parent/guardian and participant (where aged
≥8 years) perception of facial nerve recovery at 1, 3
and 6 months using a lay translation of the HB scale
8. Emotional and functional wellbeing of the
participant assessed by the parent/guardian and
participant using the Pediatric Quality of Life
Inventory (PedsQL) [39] and Child Health Utility 9D
(CHU9D)scales [40–43] and sections of the Harter
scale at 1,3, and 6 months [44].
9. Pain at 1, 3 and 6 months assessed using child
assigned visual analogue scale or Faces Pain Scale
Revised (for participants aged 5 and older) and using
a parent assigned visual analogue scale (VAS) [45–47].
Both pain scales are numbered 0–10.
10.Prevalence of synkinesis or autonomic dysfunction at 1,
3 and 6 months using the Sunnybrook scale augmented
by a synkinesis assessment questionnaire (SAQ) [48]
11.Health utilization costs assessed via CHUD9 and
via capture of information from the parent/
guardian/participant related to in-patient, out-
patient, or ED visits and to any other health facil-
ities including general practitioner attendance for
treatment or investigation during the 6 months
following randomization.
12.For patients not recovered at 6 months, recovery at
12 months as perceived by parents/guardian and
participant (where aged ≥8 years) using a lay
translation of the HB scale.
Study population
Eligible patients must be between 6 months and less than
18 years of age with ED clinician diagnosed Bell’s palsy
with onset less than 72 hours before randomisation. ED
clinicians will follow local guidelines in the diagnosis of
Bell’s palsy. Participants must fulfil all of the inclusion
criteria and none of the exclusion criteria (Table 1).
Randomisation
Participants will be randomized in a 1:1 ratio to one of two
treatment arms: intervention (prednisolone) or matchedplacebo. An independent statistician has generated a
randomization schedule using variable block sizes, stratified
by site. This schedule will be used by the central study
pharmacist at RCH to undertake the blinding, labelling and
distribution of the study drugs to participating sites by put-
ting together study packs of the required drug labelled with
sequential study numbers for each site and dosing instruc-
tions. Randomization will be undertaken at the site by ED
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pack (next pack system) from the study drug store in ED.Interventions
There is currently little evidence to assist in deter-
mining the best prednisolone dose in children. Adult
studies of Bell’s palsy have used various steroids and
doses [17–19, 29, 49]. The two large adult RCT used
50 mg prednisolone daily for 10 days [18] or 60 mg
prednisolone daily for 5 days then weaning over 5 days
[19]. The only paediatric RCT of steroid use for Bell’s
palsy used methylprednisolone 1 mg/kg/day (equivalent to
1.25 mg/kg/day prednisolone) for 10 days, then weaned
over 3–5 days [12]. Observational data from the central
study site [4], and unpublished survey data from the PRE-
DICT network indicate that prednisolone is the most fre-
quently used steroid for Bell’s palsy in children, usually
at a dose of 1 mg/kg/day for a variable number of days.
Prednisolone is also the most frequently used oral cor-
ticosteroid in children in Australia and New Zealand
for various other inflammatory conditions, with routine
doses of 1–2 mg/kg/day.
Noting the adult dose used by Sullivan et al. [18]
(50 mg for 10 days without taper); having sought advice
from endocrinologists and rheumatologists; in consider-
ation of the current local guidelines [50] and with con-
sideration to ease of preparation of study drugs, a dose
of ~1 mg/kg daily for 10 days without taper was chosen
for the current study. For the 10-day study treatment
period, participants will therefore be assigned to receive
either ~1 mg/kg/day of prednisolone (based on weight
categories) up to a maximum of 50 mg/day or to receive
matching placebo.
Adverse events from this dose and short duration are
expected to be limited to minor behavioral changes and
possible weight gain. Drug related adverse events will be
recorded. Risks should be reduced by adherence to in-
clusion and exclusion criteria listed above.
Randomization will be blinded so that trial partici-
pants, the investigator team (including the facial
image assessors), data management staff, data analysis
staff and any other clinical staff remain unaware of
the study arm to which trial participants have been
assigned to. Only the central pharmacist at RCH and
the independent statistician who generated the ran-
domisation list will be unblinded.
Prednisolone will be supplied as Redipred® oral liquid.
Redipred® contains the active ingredient prednisolone
sodium phosphate 6.72 mg/mL (equivalent to prednisol-
one 5 mg/mL). The look- and taste-matched placebo will
be supplied in 30 mL plastic bottles. The Redipred® and
matching placebo will be supplied by Aspen Pharmacare
Pty Ltd (St Leonards, NSW, Australia).All participants will receive the study drug (prednisol-
one or placebo) orally in liquid form. Participants will
receive the number of milliliters required per day based
on a pre-calculated weight-based table. The study drug
will be prescribed as a once daily dose.
The central pharmacist at RCH will blind and label
the bottles of prednisolone and placebo and place them
into study packs. The central pharmacist at RCH will
provide each site’s clinical trial pharmacy with sufficient
stock to cover the site’s projected recruitment, co-
ordinate ongoing resupply of study medication, ensure
in-date supplies are available at each site and oversee
drug accountability. Study packs will be kept in each
site’s ED in a locked, limited-access facility available for
immediate use for participant randomisation.
At the time of randomisation, the senior staff member or
medically qualified investigator in the ED will select the
lowest numbered study pack available from the study drug
store and arrange the first dose of the study drug to be ad-
ministered in the ED by a clinical nurse. The parent/guard-
ian/participant will be provided with the remaining study
drug along with instructions regarding dosing and storage.
Adherence/Compliance
Compliance/adherence will be assessed as part of the
Day 14 assessment. Families will be instructed to return
all study drug bottles at the 1 month study clinic visit
when the remaining liquid in the bottles will be
measured.
Concomitant care
All parent/guardian/participants will be provided with a
study alert card for non-study health care professionals
providing care during the study.
Emergency unblinding
The randomisation code for an individual participant
may only be unblinded in emergency situations, where
the investigator decides a participant cannot be ad-
equately treated without knowing the identity of their
treatment allocation. The randomisation code is held at
the central pharmacy at RCH.
Study procedures and assessments
Recruitment and consent
In the event of the presentation of a child with suspected
Bell’s palsy ED staff at participating sites will be asked to
notify the senior medical doctor on duty who will per-
form an initial assessment of potential eligibility. If po-
tentially eligible, the senior doctor or a member of the
investigator team will approach the participant and their
parent/guardian(s) to inform them of the study, deter-
mine their interest in participating, confirm eligibility
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consent process.
The relevant clinical teams at each site will receive
standardized, study specific education based on centrally
developed study education materials. Notification letters
about the study will be sent to relevant physicians with
consultation or referral roles at study sites.
Study procedures
An overview and the timing of the study procedures are
outlined in detail in Table 2.
Baseline assessment and randomisation during the ED visit
Following informed consent, eligibility check and ran-
domisation, demographics and relevant clinical informa-
tion will be collected from the patient including side of
the palsy, onset and associated symptoms, relevant past
medical history, and medical evaluations/contacts prior
to the ED visit.
Study assessments regarding the severity of facial palsy
as measured by the HB and Sunnybrook scales and facial
imaging (digital video recording and still photographs)Table 2 Assessment Schedule BellPIC Study
Procedure Enrolment &
Randomisation
Time point 1
Day 1
Obtain Informed consent ✓
Collect demographic and relevant information ✓
Facial images ✓
House Brackmann [18, 27] & Sunnybrook [32, 38]
scales augmented with SAQ [48]
✓
Review inclusion & exclusion criteria ✓
Randomise ✓
Study drug dispense ✓
Study drug compliance review
Adverse events review
Specialist clinician review
Emotional and functional impact using PedsQL,
CHU-9D and Harter scales [39–44]
Assessment of pain (VAS/FPS-R) [45–47]
Participant and parent perception of recovery
(lay translation of HB scale)
Collection of information on medical attendances
HB House Brackmann scale, SAQ Synkinesis Assessment Questionnaire, PedsQL Pedi
Analogue Scale, FPS-R Faces Pain Scale Revised
aThis assessment will be conducted over the telephone or on-line. A window of ±5
bA window of ± 7 days will be allowed to facilitate appointment scheduling for the
allowed to facilitate appointment scheduling or follow up contacts by phone, emai
has been assessed to have made a complete recovery (HB score of 1), they will no l
quired to complete questionnaires and scales by telephone, email or online at 3 an
cThe senior specialist clinician may be a pediatric neurologist; ENT specialist; pediat
dThis assessment will be required only for those deemed to have been not recover
facilitate follow up contacts scheduling
eAdverse events which are unresolved at 1 month should be followed till resolutionwill be conducted using standardized instructions based
on the study by Sullivan et al. [36]. A camera will be
provided to all study sites. The images will be assessed
at a later time point by assessors blinded to the study
treatment assignment for quality control purposes.
Follow up assessment at 14 days
Approximately 14 days after randomization, the parent/
guardian/participant will receive a phone call from the
study team to assess medication compliance, adverse
events and ongoing palsy symptoms (as judged subject-
ively by the parent/guardian/participant).
Follow up assessment at 1 month
One month after randomization, participants will attend
a visit at the study site. Where the participant is unable
to attend the study site, this may be completed via
videoconferencing.
A specialist clinician (a pediatric neurologist; ENT spe-
cialist; pediatrician or ED physician to accommodate site
specific resources) will review the participant to: exclude
an alternative diagnosis for the Bell’s palsy symptoms;Time
point 2
Time
point 3
Time
point 4
Time
point 5
Time
point 6
Day 14a Month 1b Month 3b Month 6b Month 12d
✓ ✓ ✓
✓ ✓ ✓
✓ ✓
✓ ✓e
✓c
✓ ✓ ✓
✓ ✓ ✓
✓ ✓ ✓ ✓ ✓
✓ ✓ ✓
atric Quality of Life inventory, CHU-9D Child Health Utility 9D, VAS Visual
days is allowed
study assessments attended on-site at 1 month; a window of ±14 days will be
l or online for study visits or contacts at 3 and 6 months. Once a participant
onger be required to attend further visits to the study clinic and will only be re-
d 6 months
rician; or ED physician
ed at their 6 month assessment. A window of ±14 days will be allowed to
or stabilisation
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determine HB grade (the primary outcome) and the
Sunnybrook scale of the Bell’s palsy; determine the pres-
ence of synkinesis or autonomic dysfunction using the
SAQ. Facial images (video recording and still photo-
graphs) will be recorded. A questionnaire will be com-
pleted by the parent/guardian or participant (age
dependent) for all participants and will elicit details on
adverse events, ongoing palsy symptoms, reports of ab-
normal hearing, lacrimation and altered taste, date of
resolution of facial palsy symptoms (if resolved) as sub-
jectively perceived by parent and any medical contact.
The following scales and tools will be completed by
the parent/guardian or participant depending on the age
of the participant (varies by scale):
o PedsQL and CHU-9D to assess the emotional and
functional wellbeing (quality of life) of the participant.
o The Harter scale to assess perceived appearance.
o FPS-R or VAS to capture pain symptoms
o A study-specific lay translation of the HB scale
A site research assistant will collect the study drug
containers from participants attending the study site for
later assessment of residual volumes and return to the
site pharmacy.
Follow up assessment at 3 and 6 months
A site research assistant will arrange a follow-up assess-
ment for any participants deemed at their previous visit
not to be fully recovered (HB score greater than 1). For
participants unable to attend the study site, assessment
will be conducted remotely as previously described.
Participants deemed to have fully recovered at the 1 month
visit will not be required to attend the study site for the
remaining study time points; the parent/guardian or partici-
pants (age dependent) will instead be asked to complete the
questionnaires online or via mail (or via telephone, adminis-
tered by the research assistant if required). The question-
naires will be the same as those completed by the
unrecovered participants but without HB, Sunnybrook,
SAQ scoring or facial imaging. Similarly, participants who
have fully recovered at the 3 month visit will not be required
to attend the study site for the 6 month time point and the
parent/guardian/participant will instead be asked to
complete the questionnaires online or via mail (or via tele-
phone, administered by the research assistant if required).
Parent/guardian or participant questionnaires, grading
scales and facial imaging will be performed similar to
the 1 month visit (see Table 1).
Follow up assessment at 12 months
For participants not recovered at 6 months, a further
contact will be conducted with the parent/guardian orparticipant with a request to complete a questionnaire
on-line or by phone to elicit information on parent per-
ceived recovery of Bell’s palsy. While this data point is
outside the RCT period of 6 months, this will allow the
determination of the 12 month recovery rate for Bell’s
palsy in children which is unknown at this time.Statistical methods
Sample size estimation
Based on observational data [4, 14] we expect 60 % of
children without prednisolone to have complete recov-
ery at 1 month. This is in line with data from the
pediatric RCT which reported complete recovery with-
out prednisolone in 72 % at 4 months [12]. A study in
adults [18] deemed an improvement of 12 % with pred-
nisolone compared with placebo to be a clinically
important difference between treatment groups. We
therefore power our study to find an increase in the pro-
portion with complete recovery from 60 % in the pla-
cebo group to 72 % in the prednisolone group. This is a
conservative estimate of efficacy compared with that
found in our observational pilot data [4, 14] which
showed an increase in complete recovery at 1 month of
16 % in those treated with prednisolone (75 %) com-
pared with those not receiving prednisolone (59 %). To
enable us to identify an increase in recovery from 60 to
72 % or larger with 80 % power requires a study with
244 subjects in each treatment group based on a two-
sided test with α = 0.05. Hence we aim to recruit 270 per
group (540 in total) to allow for 10 % loss to follow-up
at 1 month.Statistical analysis
Data will be analysed on an intention-to-treat basis. For
the primary analysis, multiple imputation will be used to
handle missing data, imputing all outcomes using a sin-
gle (joint) imputation model. Imputation will be carried
out separately by treatment arm to ensure that any treat-
ment effects are maintained. As a secondary analysis, all
analyses will be repeated using a complete case analysis,
including all participants with data available for each
outcome.
The primary outcome of complete recovery at 1 month
post randomization on the HB scale (as determined by the
site specialist clinician) will be presented as a proportion
in each treatment group, with a comparison between the
groups presented as a difference in proportions and as an
odds ratio from a logistic regression model adjusted for
site and age, with a 95 % CI and p-value. In addition, we
will present the results as Number-Needed-to-Treat
(NNT) and its 95 % CI. As an additional sensitivity ana-
lysis, the analysis of recovery at 1 month will be repeated
assuming that all participants with missing data who have
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covery 1) have recovered, and 2) have not recovered.
All secondary outcomes will be summarized by treat-
ment group. Binary outcomes will be presented as propor-
tions, with comparisons between the groups presented as
a difference in proportions and as odds ratios from logistic
regression adjusted for site, with 95 % CIs and p-values.
Continuous outcomes will be presented as means and
standard deviations, with comparisons made using linear
regression adjusted for site presented as mean differences,
95 % CIs and p-values. Time to recovery will be assessed
using a Cox proportional hazards model censoring pa-
tients who have not recovered at 6 months, with results
presented as a hazard ratio, and its 95 % CI and p-value.
Participants who have reached complete recovery at 1 or
3 months and are not assessed at the later time points will
be assumed to have complete recovery for the duration of
the study. For both the primary and secondary outcome,
we will repeat the analysis adjusted for age (as a continu-
ous variable), gender, baseline severity of facial nerve dys-
function (severe = HB V and VI, non severe = HB I-IV [18,
[36]) and time to treatment (≥24 vs >24–72 hours [18,
[36]) as potentially important confounders.
Whether the effectiveness of the intervention in im-
proving the proportion recovered at 1, 3 and 6 months
varies according to age, time to treatment and initial se-
verity will be assessed by the addition of an interaction
between treatment and the covariate to the logistic re-
gression model.
Face-to-face and video HB scores and the HB vs
Sunnybrook scoring will be compared using scatter-
plots and kappa statistics.
Finally, the effect of prednisolone compared with pla-
cebo on health economic markers will be assessed using
decision analysis using a comparison of the 6 month
treatment cost data and results from the CHU9D admin-
istered at 1 month, 3 months and 6 month.
Interim analysis and stopping rules
The study will be monitored by an independent Data
and Safety Monitoring Board (DSMB). A single interim
analysis of the primary outcome will be undertaken and
reported to the DSMB after 50 % of participants have
completed the 1 month assessment (i.e. primary out-
come data available for 244 participants). The Haybittle-
Peto rule [51] will be used as a guideline for the DSMB,
where the DSMB may recommend the trial be stopped if
the level of significance of 0.001 is reached.
Data management
All study data will be captured on study specific case re-
port forms recorded from the participants medical notes
(source data) or parental/participant questionnaires
(source data) and will be entered into and stored in asingle password protected online REDCap database with
data entry conducted at each site. Hard copy participant
data at each site will be stored in locked cabinets. RED-
Cap is hosted by MCRI. Information will be stored and
retained according to local and government regulations.
Data monitoring
The Chief Principal Investigator (PI) or designee will con-
duct site visits in order to review a selection of the data-
base against source data, verify adherence to the protocol
and confirm that research governance principles are being
upheld. Data management of entered patients will be
undertaken by the central data management team and
reviewed for completion.
Safety
Any untoward medical occurrence in a patient en-
rolled into this study regardless of its causal relation-
ship to study treatment will be recorded. Conditions
that are present at screening and do not deteriorate
will not be considered adverse events (AEs). The par-
ent/guardian/participant will be asked to report AE
when contacted at 14 days and at the 1 month follow
up visit. In addition, AEs noted during the visit or
noted from any other documentation (e.g. hospital
unit record and correspondence) will be documented
on the CRF by the investigator team.
The site PI is responsible for recording and reporting all
serious adverse events (SAEs) for the period from the first
dose until the 1 month visit. Any SAE occurring in a study
participant will be reported to the approving Human Re-
search and Ethics Committee (HREC) in accordance with
the safety reporting policy of the HREC (this timeframe is
usually between 24 and 72 hours). A suspected unex-
pected serious adverse event will in addition be reported
to the national government regulatory body (Australia or
New Zealand) within the required timelines.
Study oversight
Central study coordination will be provided by the
MCRI based study team. The trial will be overseen by a
trial steering committee (TSC) to monitor and supervise
progress of the trial; review at regular intervals relevant
information from other sources; and consider the rec-
ommendations of the DSMB.
The DSMB has an agreed upon charter and will meet
six months after commencing the trial and then every
12 months for the duration of the trial. The DSMB will
review data on safety, feasibility and protocol violations
by treatment arm but with treatment arms masked.
Once primary outcome data are available for 244 partici-
pants the DSMB will in addition review the efficacy of
the treatment arms using the stopping rule outlined
above.
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Study Management Team consisting of the site PI and a
site study coordinator/research assistant. Handling of in-
vestigational products will be the responsibility of an on-
site pharmacist.
Quality control and quality assurance
To standardise the collection of data by local investigator
teams, training of the site PI and research assistant will be
undertaken by the central coordinating team; the site PI
and site research assistant will train the remaining local
investigator team in particular the senior ED staff con-
ducting consent and randomisation as well as the special-
ist clinician(s) reviewing the participant at 1 month.
Equipment for facial images (still photographs and
video recordings) will be standardised with the same
model of camera supplied to each participating site.
Camera and video standard settings instructions along
with full usage instructions will be provided to the local
investigator teams. The local teams will not assess the
facial images for palsy but upload the images to the
study database for assessment by 3 central blinded asses-
sors for the purpose of assessing interrater reliability and
comparison of HB scoring by face-to-face assessment
versus facial images.
Ethics and dissemination
Research ethics approval
The trial has full ethics approval at the central study site
from the Royal Children’s Hospital (RCH) Human Re-
search Ethics Committee (HREC reference number RCH
HREC/15/RCHM/V4). RCH HREC is also the central
site for the National Ethics Application Form. The study
has ethics and governance approval at all 10 sites.
Consent
Parents and adolescents 12 years and older will be given
a parent/guardian/patient information sheet. After dis-
cussion with the family, written informed consent will
be obtained by the trained clinician and/or researcher in
the ED. The study investigators and/or research officer
may be involved as clinicians in the clinical care of the
patient. Parents/participants will be assured that if they
do not wish to participate this will not affect their care.
Confidentiality
Confidentiality will be ensured by storing data in a
password-protected database for which only the research
team will have the password, and paper based record
forms will be stored in locked study cupboards and of-
fices. REDcap, the research data base used across sites is
housed at the MCRI, Melbourne, Australia. Data will
only be published in de-identified, aggregated form.Dissemination policy
Results will be published in peer reviewed publications.
Discussion
This multicentre triple blind placebo controlled rando-
mised trial will allow the definitive assessment of the effi-
cacy of prednisolone in Bell’s palsy in children. It is likely
that the findings will have a high impact on clinical man-
agement strategies beyond Australia and New Zealand.
Current status
The study commenced in October 2015 and is recruit-
ing. Recruitment and data analysis is expected to be
completed in 2020.
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